Ibrutinib 140 mg helps to inhibit the growth and proliferation of malignant B-cells along with the processes of cell migration and substrate adhesion. It belongs to kinase inhibitor category of drugs.
Ibrucent 140 mg capsules are indicated for the treating patients with:
- Mantle cell lymphoma (MCL) who have previously been treated with at least one prior therapy.
- Chronic lymphocytic leukemia (CLL) who have received at least one prior therapy
- Chronic lymphocytic leukemia with 17p deletion mutation
- Waldenström’s macroglobulinemia (WM)
The most common adverse reactions with Ibrucent 140 mg are:
- Decrease in WBC counts
- Decrease in platelet counts
- Loose motions
- Tiredness and fatigue
- Musculoskeletal aches
- Easy bruising and bleeding
- Nausea and vomiting
- Infections of the upper respiratory tract
This is not the full list of all side effects that may occur with Ibrucent. Please seek help from your doctor regarding unusual side effects. You must seek immediate medical help if you find serious symptoms arising due to decreased blood cell counts.
Drug allergies are quite common. The most common side effects of allergies are: itching, rashes, hives, shortness of breath, low blood pressure, dizziness and loose motions.
Warnings and precautions
Patients taking Ibrucent should be closely monitored for:
- Atrial Fibrillation, Second Primary Malignancies, Tumor Lysis Syndrome
- Not to be consumed by pregnant women.
- You must always inform your doctor about your past and present drug allergies, other substance allergies Ibrucent 140 mg. Drug allergies to both active ingredients and inactive agents are common.
- Before using Ibrucent 140 mg, inform your doctor or pharmacist regarding relevant medical history, especially that related to bleeding tendency, heart diseases, lung and liver ailments. Also, inform about all the drugs you are presently taking.